Volume | 9,409 |
|
|||||
News | - | ||||||
Day High | 6.22 | Low High |
|||||
Day Low | 6.05 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
ESSA Pharma Inc | EPIX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
6.12 | 6.05 | 6.22 | 6.12 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
62 | 9,409 | $ 6.13 | $ 57,702 | - | 2.56 - 11.67 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
10:16:34 | 1 | $ 5.9198 | USD |
ESSA Pharma Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
265.87M | 44.24M | - | 0 | -26.58M | -0.60 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
ESSA Pharma News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical EPIX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 6.78 | 7.25 | 5.9228 | 6.38 | 92,185 | -0.69 | -10.18% |
1 Month | 8.59 | 8.6779 | 5.9228 | 7.29 | 57,829 | -2.50 | -29.10% |
3 Months | 8.95 | 11.67 | 5.9228 | 9.31 | 124,132 | -2.86 | -31.96% |
6 Months | 4.06 | 11.67 | 3.8901 | 7.77 | 128,799 | 2.03 | 50.00% |
1 Year | 2.70 | 11.67 | 2.56 | 6.08 | 107,587 | 3.39 | 125.56% |
3 Years | 27.13 | 36.00 | 1.40 | 6.52 | 490,175 | -21.04 | -77.55% |
5 Years | 2.27 | 36.00 | 1.40 | 7.62 | 334,318 | 3.82 | 168.28% |
ESSA Pharma Description
ESSA Pharma Inc is a pharmaceutical company. The company is in the preclinical stage, focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer. The company is developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. |